Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Chi-Med’s Surufatinib Study Meets Primary Endpoint Early | Contract Pharma

What are you searching for?

Sign in
Breaking News

Chi-Med’s Surufatinib Study Meets Primary Endpoint Early

Stops Phase III study of surufatinib in advanced neuroendocrine tumors, meeting the primary endpoint of progression free survival

By: Cassandra Gervolino

Hutchison China MediTech Ltd. announced that the independent Data Monitoring Committee (IDMC) of the Phase III study of surufatinib in advanced neuroendocrine tumors – extra-pancreatic (SANET-ep) has completed a planned interim analysis. The IDMC determined that the study has already met the pre-defined primary endpoint of progression free survival (PFS) and as a result the study will be stopped.

Chi-Med will now arrange for a pre-New Drug Application (NDA) meeting with the China National Medical Products Administration (NMPA) to discuss the preparation of the NDA for surufatinib for this indication. They intend to submit the results of the SANET-ep study for presentation at an upcoming scientific conference.  

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters